Seattle-based VPDiagnostics has secured a $2.9 million grant from the National Institutes of Health to run a clinical trial of its MRI-based technology for determining whether patients are at high risk of stroke. The trial is expected to enroll about 300 patients, and will track them for 18 months, says Mike Hartmann, vice president of business and product development. The technology is based on more than 15 years of research at the University of Washington.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
